UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The TLR4 antagonist Eritoran protects mice from lethal influenza infection

Nature (London), 2013-05, Vol.497 (7450), p.498-502

2013

Volltextzugriff (PDF)

Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist

The Journal of pharmacology and experimental therapeutics, 2003-03, Vol.304 (3), p.1093-1102

2003

Volltextzugriff (PDF)

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial

JAMA : the journal of the American Medical Association, 2013-03, Vol.309 (11), p.1154

2013

Volltextzugriff (PDF)

Blocking of Responses to Endotoxin by E5564 in Healthy Volunteers with Experimental Endotoxemia

The Journal of infectious diseases, 2003-02, Vol.187 (4), p.631-639

2003

Volltextzugriff (PDF)

Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2004-09, Vol.48 (9), p.3233-3240

2004

Volltextzugriff (PDF)

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

Clinical cancer research, 2011, Vol.17 (1), p.193-200

2011

Volltextzugriff (PDF)

LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation

The Journal of clinical investigation, 2001-06, Vol.107 (12), p.1581-1589

2001

Volltextzugriff (PDF)

Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]

The Journal of pharmacology and experimental therapeutics, 2004-01, Vol.308 (1), p.175-181

2004

Volltextzugriff (PDF)

A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity

The Journal of pharmacology and experimental therapeutics, 2002-02, Vol.300 (2), p.655-661

2002

Volltextzugriff (PDF)

Inhibition of endotoxin response by synthetic TLR4 antagonists

Current topics in medicinal chemistry, 2004-01, Vol.4 (11), p.1147-1171

2004

Volltextzugriff (PDF)

A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass

Anesthesia and analgesia, 2007-02, Vol.104 (2), p.378-383

2007

Volltextzugriff (PDF)

Association of the Endotoxin Antagonist E5564 with High-Density Lipoproteins In Vitro: Dependence on Low-Density and Triglyceride-Rich Lipoprotein Concentrations

Antimicrobial Agents and Chemotherapy, 2003-09, Vol.47 (9), p.2796-2803

2003

Volltextzugriff (PDF)

Consequences of Interaction of a Lipophilic Endotoxin Antagonist with Plasma Lipoproteins

Antimicrobial Agents and Chemotherapy, 2000-03, Vol.44 (3), p.504-510

2000

Volltextzugriff (PDF)

TLR4 antagonists for endotoxemia and beyond

Current opinion in investigational drugs (London, England : 2000), 2005-05, Vol.6 (5), p.496

2005

Volltextzugriff (PDF)

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers

Innate immunity (London, England), 2008-12, Vol.14 (6), p.383-394

2008

Volltextzugriff (PDF)

Suppression of Murine Endotoxin Response by E5531, a Novel Synthetic Lipid A Antagonist

Antimicrobial Agents and Chemotherapy, 1998-11, Vol.42 (11), p.2824-2829

1998

Volltextzugriff (PDF)

Lipoprotein Distribution of a Novel Endotoxin Antagonist, E5531, in Plasma from Human Subjects with Various Lipid Levels

Antimicrobial Agents and Chemotherapy, 1999-10, Vol.43 (10), p.2562-2564

1999

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men

Innate immunity (London, England), 2012-12, Vol.18 (6), p.793-803

2012

Volltextzugriff (PDF)

Influence of Plasma Cholesterol and Triglyceride Concentrations and Eritoran (E5564) Micelle Size on its Plasma Pharmacokinetics and Ex Vivo Activity Following Single Intravenous Bolus Dose Into Healthy Female Rabbits

Pharmaceutical research, 2008, Vol.25 (1), p.176-182

2008

Volltextzugriff (PDF)

E5531, a synthetic non‐toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide

British journal of pharmacology, 1999-06, Vol.127 (4), p.853-862

1999

Volltextzugriff (PDF)

E5531, a Pure Endotoxin Antagonist of High Potency

Science (American Association for the Advancement of Science), 1995-04, Vol.268 (5207), p.80-83

1995

Volltextzugriff (PDF)

A phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a upid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass

Anesthesia and analgesia, 2007, Vol.104 (2), p.378-383

2007

Volltextzugriff (PDF)

Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue

Journal of endotoxin research, 2002-12, Vol.8 (6), p.483-488

2002

Volltextzugriff (PDF)

Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue

Journal of endotoxin research, 2002-01, Vol.8 (6), p.483-488

2002

Volltextzugriff (PDF)

Pumiliotoxin B Binds to a Site on the Voltage-Dependent Sodium Channel that is Allosterically Coupled to Other Binding Sites

Proceedings of the National Academy of Sciences - PNAS, 1988-02, Vol.85 (4), p.1272-1276

1988

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(87)
Buchkapitel
(2)

Sprache

Englisch
(89)

Erscheinungsjahr

n.n

Thema

Science & Technology
(81)
Life Sciences & Biomedicine
(71)
Humans
(55)
Animals
(27)
Male
(27)
Genetics & Heredity
(25)
Biological And Medical Sciences
(21)
Female
(21)
Adult
(16)
Medical Sciences
(16)
Lipid A - Analogs & Derivatives
(15)
Middle Aged
(15)
Pharmacology & Pharmacy
(12)
Lipopolysaccharides - Antagonists & Inhibitors
(10)
Mice
(10)
Pharmacology. Drug Treatments
(10)
Phenotype
(10)
Child
(9)
Life Sciences
(9)
Lipid A - Pharmacology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The TLR4 antagonist Eritoran protects mice from lethal influenza infection

Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial

Blocking of Responses to Endotoxin by E5564 in Healthy Volunteers with Experimental Endotoxemia

Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation

Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]

A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity

Inhibition of endotoxin response by synthetic TLR4 antagonists

A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass

Association of the Endotoxin Antagonist E5564 with High-Density Lipoproteins In Vitro: Dependence on Low-Density and Triglyceride-Rich Lipoprotein Concentrations

Consequences of Interaction of a Lipophilic Endotoxin Antagonist with Plasma Lipoproteins

TLR4 antagonists for endotoxemia and beyond

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers

Suppression of Murine Endotoxin Response by E5531, a Novel Synthetic Lipid A Antagonist

Lipoprotein Distribution of a Novel Endotoxin Antagonist, E5531, in Plasma from Human Subjects with Various Lipid Levels

Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men

Influence of Plasma Cholesterol and Triglyceride Concentrations and Eritoran (E5564) Micelle Size on its Plasma Pharmacokinetics and Ex Vivo Activity Following Single Intravenous Bolus Dose Into Healthy Female Rabbits

E5531, a synthetic non‐toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide

E5531, a Pure Endotoxin Antagonist of High Potency

A phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a upid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass

Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue

Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue

Pumiliotoxin B Binds to a Site on the Voltage-Dependent Sodium Channel that is Allosterically Coupled to Other Binding Sites

Suchergebnisse filtern